Uroxatral

• Antihypertensive Agents
• ATC:G04CA01

• Uroxatral
• Xatral

• No information avaliable

C₁₉H₂₇N₅O₄

http://www.rxlist.com/cgi/generic3/uroxatral.htm

Uroxatral FDA

No information avaliable

389.449 g/mol

No information avaliable

No information avaliable

Solid

1.604

Tablet (extended-release)

For the treatment of the signs and symptoms of benign prostatic hyperplasia.

Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.

Absorption is 50% lower under fasting conditions

side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

PATIENT INFORMATION

Follow the links

http://www.rxlist.com/cgi/generic3/uroxatral_pi.htm

http://www.rxlist.com/cgi/generic3/uroxatral_wcp.htm

http://www.drugs.com/cons/Alfuzosin.html

Humans and other mammals